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Abstract
COVID-19 (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) is associated with coagulopathy through numerous mechanisms. The reported incidence of
venous thromboembolism (VTE) in hospitalized patients with COVID-19 has varied
widely, and several meta-analyses have been performed to assess the overall prevalence of VTE. The novelty of this coronavirus strain along with its unique mechanisms
for microvascular and macrovascular thrombosis has led to uncertainty as to how to
diagnose, prevent, and treat thrombosis in patients affected by this virus. This review discusses the epidemiology and pathophysiology of thrombosis in the setting of
SARS-CoV-2 infection along with an updated review on the preventative and treatment strategies for VTE associated with SARS-CoV-2 infection.
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Essentials
• Covid-19 (severe acute respiratory syndrome coronavirus 2) is associated with an increased risk of blood clots.
• The cause of blood clots in the setting of COVID-19 infection is complex.
• Screening and workup for blood clots largely remains up to treating physicians.
• Data regarding the optimal prevention and treatment of blood clots is evolving.
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performed diagnostic imaging solely based on clinical suspicion. 8
Similarly, a meta-analysis reported by Hasan et al9 reported a VTE

The novel coronavirus COVID-19 (severe acute respiratory syndrome

prevalence of 31% in patients with COVID-19 requiring an ICU level

coronavirus 2 [SARS-CoV-2]) has led to a global pandemic, with over

of care, despite the use of prophylactic or therapeutic anticoagula-

272 598 201 cases and 5 334 221 deaths as of December 16, 2021

tion. When compared to non–COVID-19 medical inpatients, Li et al10

(https://coronavirus.jhu.edu/map.html; accessed December 16,

reported a COVID-19–associated VTE odds ratio (OR) of 2.79 and

2021). In addition to respiratory complications, early reports dis-

5.94 for hospitalized patients with nonsevere and severe COVID-19,

cussed higher rates of venous thromboembolism (VTE) in patients

respectively. Nopp et al11 performed a meta-analysis with subgroup

with severe COVID-19 disease compared to data from similar pa-

analysis based on an ICU versus a non-ICU setting and DVT screen-

1-3

Coagulation abnormalities are

ing versus no screening. The overall VTE prevalence was 14.1%, with

common in patients with COVID-19, and those with severe illness

higher rates found in patients with ultrasound screening versus no

frequently have elevated coagulation markers, such as D-dimer and

screening (40.3% and 9.5%, respectively). VTE prevalence was lower

fibrinogen degradation product, with several proposed mechanisms

(7.9%) in non-ICU patients compared to those who required an ICU

tients not affected by SARS-CoV-2.

of hypercoagulability.

4,5

As such, preventing and treating VTE in

level of care (22.7%).

patients with COVID-19, particularly in the inpatient setting, is of
paramount importance.

The reported rates of venous thrombosis in the published randomized control trials that aimed to assess clinical outcomes using
different doses of anticoagulation (standard prophylactic dose vs

2
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higher-than-standard dose anticoagulation) are noted in Table 1.
Aside from the HEP-COVID trial,12 which reported thromboembolism in 29% in a standard anticoagulation dose group versus 10.9% in

The increased risk of VTE in severe SARS-CoV-2 infection was re-

a therapeutic anticoagulation dose group, these trials reported much

ported early in the pandemic, although there has been a high variability

lower rates of VTE compared to rates noted in the observational

of reported rates. In one of the first reports, Cui et al1 retrospectively

studies. The difference in these rates may reflect early reporting bias

evaluated 81 patients with severe COVID-19 hospitalized in a single

in addition to current early diagnostic and treatment strategies (ie,

institution in China and reported 25% (20/81) of intensive care unit

antiviral/corticosteroids that have since become standard of care).

(ICU) patients developed VTE. In this study, no preventative antico-

It is important to note, however, that these trials were not powered

agulant was administered. Another early report from the Netherlands

for venous thrombosis as a primary end point. However, the true

described a similar VTE incidence of 27% in patients with severe

incidence of VTE may be even higher than reported in these studies,

COVID-19 admitted to the ICU, despite the use of pharmacologic VTE

as pulmonary embolism (PE) may be the cause of sudden respiratory

6

prophylaxis. Other institutions have reported a smaller incidence of

decompensation in severely ill patients with COVID-19. A German

VTE. For example, data from the Brigham and Women’s Hospital re-

autopsy study of patients who died of COVID-19 revealed venous

ported a 14-day cumulative incidence of symptomatic VTE of 9.3% in

thrombosis in 58% of patients, in whom VTE was not suspected be-

patients with COVID-19 who required an ICU level of care.7 The varia-

fore death. In this study, PE was the cause of death in 4 of 12 au-

bility in reporting is likely due to several confounders including individ-

topsy specimens.13 Another autopsy study described thrombosis of

ual institutions’ VTE prophylaxis strategy, length of study, deep vein

small and midsized pulmonary arteries in all 11 patients examined.14

thrombosis (DVT) screening procedures, patient selection, reporting
bias, and outcome definitions. Several meta-analyses and pooled aggregates have been published in an attempt to describe a more ac-

3
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curate depiction of the prevalence of VTE in patients with COVID-19.
A meta-analysis of 21 studies that included nearly 2000 patients

The RIETE registry is an ongoing, international, multicenter pro-

with COVID-19 reported that the weighted mean prevalence (WMP)

spective registry of patients with acute VTE. This group analyzed

of VTE was 31.3%, with similar results seen in ICU patients (WMP,

clinical features and outcomes of 455 patients with COVID-19

32.7%) and in those who received standard VTE prophylaxis (WMP,

who had a VTE during their hospital admission. In this registry,

23.9%). The WMP of VTE was 37.1% in studies that employed routine

men comprised 71% of the population, and the median age was

DVT screening, whereas the WMP of VTE was 29.4% in studies that

65 years. The vast majority of events were PEs (83%), while 17%

|
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had isolated DVT. At the time of VTE diagnosis, 88% were receiv-

3 of 15

which activate the contact pathway of coagulation. 29 Complement

ing pharmacologic VTE prophylaxis. The mortality rate was 12%

activation, endothelial injury, platelet activation, and cytokines such

within 10 days, and 2.9% of patients had a major bleeding event.15

as IL-6 also play notable roles in thrombogenesis.30,31 There have

Hematologic and inflammatory laboratory abnormalities have

also been several reports of positive antiphospholipid antibodies

been found to correlate with disease severity in patients with

in critically ill patients with COVID-19.32-35 However, it is not clear

COVID-19. Specifically, elevations in fibrinogen, fibrinogen degrada-

whether these antibodies are reactive (as often seen in critical illness),

tion product, C-reactive protein (CRP), interleukin-6 (IL-6), erythro-

or whether they contribute to a direct causative role of developing

cyte sedimentation rate (ESR), and D-dimer have been found to be

thrombosis. Stringent design of data collection and interpretation

associated with increased severity of disease.16-18 Severe thrombo-

is needed to understand the role of antiphospholipid antibodies in

cytopenia and lymphopenia have also been associated with poorer

COVID-19 coagulopathy. Overall, the coagulopathy of COVID-19

outcomes, both independently and in the setting of disseminated

likely results from a mixture of inflammation with endothelial dys-

intravascular coagulation (DIC).19,20 Obtaining these clinical param-

function, low grade DIC, and microvascular thrombosis (Figure 1).

eters may provide further information for the prediction of VTE (as
discussed below) as well as overall prognosis.

4
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With the known risks of micro- and macrovascular thromboses, there
have been numerous attempts to identify predictive biomarkers for

Hospitalized patients with COVID-19 share many risk factors for

VTE in patients with COVID-19. The previously mentioned early re-

VTE as traditional inpatients including older age, obesity, ICU level of

port from Cui et al1 reported that VTE was associated with a lower

care, and immobility. However, in addition to these well-established

lymphocyte count, longer activated partial thromboplastin time

VTE risk factors, severe SARS-CoV-2 infection is associated with

(aPTT), and higher D-dimer quantification. Quantitative D-dimer was

coagulopathy and an inherent increased risk of thromboembolic

one of the first biomarkers studied in patients with COVID-19. A mul-

complications. 21

ticenter retrospective study reported by Al-Samkari et al36 quantified

Early reports from China described the risk of mortality from

that D-dimer >2500 had an adjusted OR of 6.79 for developing throm-

severe SARS-CoV-2 infection was associated with older age in ad-

bosis. Additional biomarkers predictive of VTE in this study included

dition to an abnormal coagulation profile similar to DIC. 22 In this

platelet count >450 × 109/L (adjusted OR, 3.56), CRP > 100 mg/L (ad-

study, 71% of nonsurviving patients with COVID-19 meet criteria for

justed OR, 2.71), and ESR >40 mm/h (adjusted OR, 2.64). However,

DIC using the ISTH criteria. 23 There are, however, some differences
between traditional DIC seen in sepsis and the coagulopathy seen

this study also reported that D-dimer was associated with increased
bleeding (adjusted OR, 3.56). Another study found that male sex, el-

in patients with severe COVID-19. For example, DIC due to sepsis

evated admission CRP, and elevated admission platelet count were

usually results in a more profound consumptive coagulopathy and

associated with VTE risk in a univariate analysis, although only male

thrombocytopenia compared to the coagulopathy seen in patients

sex continued to show predictions in the multivariate analysis.7 It is

with COVID-19. 24 It is proposed that the relative lack of consump-

known that men are at increased risk for recurrent VTE compared to

tive coagulopathy may be why patients with COVID-19 are more

women, but the risk of a first VTE is similar among both sexes. It is

prothrombotic rather than disease evolution into a bleeding propen-

postulated that men are more at risk than women when hospitalized

sity due to hyperfibrinolysis. Also in SARS-CoV-2 infection, there

for COVID-19 because those hospitalized in the initial waves of the

is a predilection for thrombotic microangiopathy to affect the lung

pandemic were typically older adults, which removes the traditional

vasculature, rather than widespread systemic organ damage from

VTE risk factors in women such as oral contraception and pregnancy.

microthrombosis. 25 Several studies have reported widespread mi-

Dujardin et al37 retrospectively evaluated several clinical vari-

croangiopathy and thrombosis within the pulmonary vasculature of

ables including positive end-expiratory pressure, ratio of arterial ox-

14,26,27

patients with COVID-19.

Localized pulmonary thrombi may be

ygen partial pressure to fractional inspired oxygen, platelet count,

one mechanism for the predilection of PE over DVT in patients with

international normalized ratio (INR), aPTT, fibrinogen, antithrombin,

COVID-19. It has been postulated that localized pulmonary thrombi

D-dimer, and CRP in an effort to predict VTE in critically ill patients

(as opposed to PE) may develop as a consequence of pulmonary vas-

with COVID-19. In this study, elevated CRP and D-dimer had the

cular damage and severe localized inflammation.

27

highest positive predictive value with an area under the curve (AUC)

COVID-19 is thought to promote coagulation by several mecha-

of 0.75 and 0.64, respectively. Similarly, in non-ICU patients with

nisms. The virus interacts with the angiotensin-converting enzyme

COVID-19, a prospective study evaluating patients for asymptomatic

2 receptor on endothelial cells, which can cause severe endothelial

DVT reported an elevated D-dimer (defined as >1000 ng/mL) had an

inflammation with a resultant shift toward a procoagulant state with
microvascular coagulopathy.

28

The robust inflammatory response is

AUC of 0.72.38 The timing and type of D-dimer assays are important

considerations when applying these findings to clinical practice.

thought to play a primary role in COVID-19–induced coagulopathy

One study demonstrated that an elevated prothrombin fragment

by several mechanisms. Microorganisms accumulate polyphosphates,

1.2 was potentially more discriminant than D-dimer for identifying

Therapeutic-dose
anticoagulation with
heparin or LMWH
vspharmacologic
thromboprophylaxis in
accordance with local
usual care

Non–critically ill at
enrollment

Hospitalized with
elevated D-dimer

ATTACC,
ACTIV-4 a,
and REMAP-
CAP52

ACTION53
Therapeutic (rivaroxaban
if clinically stable
or enoxaparin if
clinically unstable)
vs prophylactic
anticoagulation (UFH
or LMWH)

Therapeutic-dose
anticoagulation with
heparin or LMWH
vs pharmacologic
thromboprophylaxis in
accordance with local
usual care

ICU-level respiratory
or cardiovascular
organ support

ATTACC,
ACTIV-4 a,
and REMAP-
CAPe50

Enoxaparin, 1 mg/kg daily
vs enoxaparin, 40 mg
dailya

Enoxaparin, 1 mg/kg daily
vs enoxaparin, 40 mg
dailyc

ICU

Interventions

Hospitalized with
severe COVID
defined as ICU
admission and/
or modified ISTH
Overt DIC score ≥3

48

Patient population

Zed49

INSPIRATION

Clinical trial

Time to death, duration
of hospitalization,
or duration of
supplemental
oxygen

Organ support–free
days

Organ support–free
days

All-c ause mortality

Composite of venous or
arterial thrombosis,
treatment with
ECMO, or mortality
within 30 days

Primary efficacy
outcome

615

2219

1207

176

600

Total
participants

30 days

21 days

21 days

30 days

30 days

Follow up

Composite thrombotic outcome
and all-c ause death occurred
in 15% (n = 46) in the
therapeutic anticoagulation
group and in 14% (n = 44)
in the prophylactic
anticoagulation group (RR,
1.04; 95% CI, 0.70-1.50;
P = .91)

Probability that therapeutic-dose
anticoagulation increased
organ support–free days as
compared with usual care
thromboprophylaxis was
98.6% (adjusted odds ratio,
1.27; 95% credible interval,
1.03-1.58)

Therapeutic-dose anticoagulation
group’s median value for
organ support–free days was
1 (interquartile range, −1 to
16). Those assigned to usual
care prophylaxis the median
value was 4 (interquartile
range, −1 to 16)

Primary outcome occurred
in 21% (n = 18) of those
who received standard
dose prophylaxis and in
15% (n = 13) of those who
received intermediate dose
(odds ratio, 0.66; 95% CI,
0.30-1.45; P = .31

Primary outcome occurred in
45.7% (n = 126) of patients
who received intermediate-
dose anticoagulation and
in 44.1% (n = 126) of those
who received standard-dose
prophylaxis (odds ratio, 1.06;
95% CI, 0.76-1.48; P = .70)

Efficacy results

TA B L E 1 Published randomized controlled trials evaluating VTE prophylactic strategies in hospitalized patients with COVID-19

VTE occurred in 4%
(n = 11) in therapeutic
anticoagulation
group vs. 6% (n = 18)
in prophylactic
anticoagulation group (RR,
0.60; 95% CI, 0.29-1.25;
P = .19)

Arterial or VTE occurred
in 1.1% (n = 13) in
therapeutic dose vs 2.1%
(n = 22) in usual care
prophylaxis

Arterial or VTE occurred
in 7.2% (n = 38) in
therapeutic dose vs 11.1%
(n = 62) in usual care
prophylaxis

VTE occurred in 7% (n = 6)
in standard dose vs. 8%
(n = 7) in intermediate
dose (odds ratio, 1.79;
95% CI, 0.51-6.25; P > .95)

VTE occurred in 3.3% (n = 9)
in intermediate dose vs
3.5% (n = 10) in standard
dose (odds ratio, 0.93;
95% CI, 0.37-2 .32;
P = .87)

Thrombotic event rate

Major bleed or CRNMBd
occurred in 8% (n = 26)
in the therapeutic
anticoagulation group
and in 2% (n = 7)
in the prophylactic
anticoagulation group
(RR, 3.64; 95% CI,
1.61-8 .27; P = .001)

Major bleedingd occurred
in 1.9% (n = 22) of
the patients receiving
therapeutic-dose
anticoagulation
and in 0.9% (n = 9)
of those receiving
thromboprophylaxis

Major bleedd occurred
in 3.8% (n = 20) in
the therapeutic dose
anticoagulation arm vs
2.3% (n = 13) in usual
care arm (adjusted
odds ratio, 1.48; 95%
CI, 0.75-3.04)

Major bleedd 2% (n = 2)
in both arms; minor
bleed 7% (n = 6) in
both arms; P > .99 for
both major and minor
bleeding

Major bleedb occurred
in 2.5% (n = 7) in the
intermediate-dose
group and in 1.4%
(n = 4) in those who
received standard
prophylaxis (odds
ratio, 1.83; 1-sided
97.5% CI, 0.00-5.93,
not meeting the
noninferiority criteria;
P for noninferiority
0.99)

Safety results

4 of 15
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Hospitalized adult
patients with
COVID-19 with
D-dimer levels >4
times the upper
limit of normal or
sepsis-induced
coagulopathy score
of ≥4

Adults admitted to
hospital wards with
COVID-19 and
increased D-dimer
levels

HEP-COVID12

RAPID54
Therapeutic-dose or
prophylactic-dose
heparin (low-
molecular-weight
or unfractionated
heparin)

Standard prophylactic
or intermediate-
dose LMWH or
unfractionated heparin
vs therapeutic-dose
enoxaparin

Interventions

Composite of death,
invasive mechanical
ventilation,
noninvasive
mechanical
ventilation, or
admission to an
ICU

Venous
thromboembolism,
arterial
thromboembolism,
or death from any
cause

Primary efficacy
outcome

465

257

Total
participants

28 days

30 ± 2 days

Follow up

Primary outcome occurred
in 16.2% assigned to
therapeutic heparin and
in 21.9% assigned to
prophylactic heparin (odds
ratio, 0.69; 95% CI, 0.43-1.10;
P = .12)

Primary outcome occurred
in 41.9% in the standard-
dose group vs 28.7% in
the therapeutic-dose
group. RR, 0.68; 95% CI,
0.49-0.96); P = .03

Efficacy results

Venous thromboembolism
occurred in two patients
(0.9%) assigned to
therapeutic heparin and
six (2.5%) assigned to
prophylactic heparin
(odds ratio, 0.34; 95% CI,
0.07-1.71; P = .19)

thromboembolism (29.0% in
standard –dose group vs
10.9% in therapeutic dose
group. RR, 0.37 95% CI,
0.21–0.66; p < 0.001)

Thrombotic event rate

Major bleeding occurred
in two patients
(0.9%) assigned
to therapeutic
heparin and four
(1.7%) assigned to
prophylactic heparin
(odds ratio, 0.52; 95%
CI, 0.09-2 .85; P = .69)

2 major bleeds (1.6%) in
the standard-dose vs
6 major bleeds (4.7%)
in the therapeutic-
dose groups (RR,
2.88; 95% CI,
0.59–14.02; p = 0.17)

Safety results

According to the Bleeding Academic Research Consortium.

Trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation.

e

According to ISTH criteria.

Adjusted for obesity.

d

c

b

With modification according to body weight and creatinine clearance.

a

Abbreviations: CI, confidence interval; CRNBM, clinically relevant nonmajor bleeding; DIC, disseminated intravascular coagulation; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit;
LMWH, low-molecular-weight heparin; RR, relative risk; UFH, unfractionated heparin; VTE, venous thromboembolism.

Patient population

Clinical trial

TA B L E 1 (Continued)
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F I G U R E 1 Prothrombotic state of COVID-19 infection. The pathogenesis of the hypercoagulable state of COVID-19 infection is depicted
above. Bottom left: COVID-19 infection can lead to a robust immune response with resultant secretion of cytokines (such as interleukin-6
[IL-6]), antiphospholipid antibodies (APLA), and neutrophil extracellular traps (NETosis). Bottom right: COVID-19 infection also leads
to complement activation in addition to endothelial dysfunction and organ injury which increases procoagulant molecules such as von
Willebrand factor and factor VIII. Top left: Liver injury can occur due to endotheliopathy, which leads to an overall increase in inflammatory
markers such as fibrinogen, CRP (C Reactive Protein) and thrombopoietin (TPO). Top right: Acute infection can have a variable effect on the
platelet (PLT) count and the D-dimer is elevated in the setting of fibrinolysis of micro- or macrovascular thrombosis
thrombotic manifestations in hospitalized patients with COVID-19.39

the most common theme was to take an individualized approach to

While this could provide a helpful biomarker tool, this study was small,

patient management and that randomized controlled trials (RCTs) to

with only 115 patients, and thus, more research is required. Other

address these important anticoagulation issues are much needed.44

laboratory values such as prothrombin time, aPTT, ferritin, procalci-

Given the observation of increased thrombotic events, especially in

tonin, lactate dehydrogenase, and troponin have also been studied,

patients with more severe disease, higher-than-prophylactic doses of

but there is no clear correlation with VTE in patients with COVID-19.

anticoagulation were used during the early phase of the pandemic.

However, to date, there are no specific and reliable laboratory values

However, the retrospective observational data for such intermediate

to predict for VTE in patients with COVID-19. Given this challenge,

or therapeutic dosing has been mixed; some studies showed a poten-

clinicians should be diligent in assessing their patients for potential

tial improvement in outcomes with higher doses of anticoagulation in

thromboses and, if symptoms occur, imaging evaluations should be

some, but no difference or worse outcomes in others.45-47

obtained to confirm thrombosis and guide anticoagulation strategies.

There are now emerging data from prospective randomized trials
to address the question of optimal thromboembolism prophylaxis.

6
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Of note, these trial outcomes were composite outcomes of thromboembolism or clinical deterioration that might be related to immune-
mediated inflammatory microthrombosis. A RCT of 600 critically ill

In addition to differing protocols for obtaining imaging studies

patients positive for COVID-19, the INSPIRATION study, comparing

(symptomatic versus screening), another contributing factor for the

standard prophylactic dosing of primarily enoxaparin (40 mg daily)

disparate rates of VTE reported across institutions may be due to the

with intermediate dose enoxaparin (1 mg/kg daily for most pa-

varying practices surrounding the use of prophylactic anticoagula-

tients), found that there was no difference in the rates of venous

tion. Because COVID-19 has been associated with thrombotic com-

or arterial thrombosis, treatment with extracorporeal membrane

plications, there has been an intense debate surrounding the optimal

oxygenation, or mortality within 30 days (OR, 1.06; 95% CI, 0.76-

prophylactic anticoagulation management for these patients. Several

1.48; P = .70).48 The Zed trial, a multicenter, open-label, randomized

studies early in the pandemic demonstrated improved survival and

study, compared standard- versus intermediate-dose enoxaparin in

lower VTE rates with the use of pharmacologic VTE prophylaxis.40-43

176 patients with COVID-19 requiring an ICU level of care and in

However, there is an ongoing debate about using higher-than-

those with a modified ISTH Overt DIC score of ≥3. Similar to what

standard prophylactic anticoagulation (intermediate or therapeutic

was seen in the INSPIRATION trial, there was no difference in over-

doses of anticoagulation) in inpatients with COVID-19. A recent re-

all mortality, thrombosis, or bleeding between the two arms (OR for

view comparing and contrasting major societal guidelines found that

primary efficacy outcome was 0.66; 95% CI, 0.30-1.45; P = .31).49

|
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A conglomerate of three open-label, harmonized, adaptive inter-

received an intermediate dose of anticoagulation had a major bleed-

national multicenter RCTs (ATTACC, ACTIV-4a, and REMAP-C AP)

ing incidence of 2.5% compared to 1.4% in the standard-dose pro-

evaluated therapeutic dose anticoagulation (≈90% low-molecular-

phylactic group.48 In the critically ill population, The REMAP-C AP,

weight heparin [LMWH]) versus usual care prophylaxis (composed

ACTIV-4a, and ATTACC Investigators report that major bleeding oc-

of standard-  or intermediate-dose anticoagulation) in hospitalized

curred in 3.8% of patients who received therapeutic anticoagulation

patients with COVID-19. The authors report that in critically ill pa-

compared to 2.3% of patients who received usual care pharmaco-

tients (defined as presence of critical care support at enrollment),

logic prophylaxis.50 In the Hep-COVID trial, major bleeding occurred

therapeutic dose anticoagulation with heparin or LMWH did not

in 1.6% in the standard-dose group versus 4.7% in the therapeutic-

lead to improved probability of survival to hospital discharge nor did

dose group (relative risk, RR, 2.88; 95% CI, 0.59-14.02; P = .17).12

it lessen the days requiring organ support. 50 Interestingly, the same
trial showed therapeutic anticoagulation (compared to usual care

Additional bleeding rates from published trials are listed in Table 1.
Bleeding in this population may be related to thrombocytopenia, hy-

dosing) led to fewer days requiring organ support in non–critically ill

perfibrinolysis, and coagulation abnormalities along with therapeu-

patients with COVID.51,52 The ACTION trial randomized 615 hospi-

tic interventions including invasive procedures and anticoagulation

talized patients with COVID-19 with elevated D-dimer and compared

itself. These data highlight the importance of balancing the risk of

therapeutic (rivaroxaban 20 mg daily for most patients) for 30 days

bleeding when considering thromboprophylaxis in this population.

to standard prophylactic anticoagulation. Treatment with therapeu-

Given these data, the ideal dose for thromboprophylaxis is

tic anticoagulation did not improve mortality, duration of hospital-

evolving in hospitalized patients with COVID-19. Current data out-

ization, or duration of oxygen use.53 The most recent published trial,

line that standard dosing of thromboprophylaxis in severely ill pa-

the HEP-COVID trial, evaluated therapeutic LMWH versus standard

tients with COVID-19 requiring organ support in critical care units is

or intermediate dose thromboprophylaxis in high-risk hospitalized

appropriate. Paradoxically however, patients with less severe illness

patients with a D-dimer level greater than 4× the upper limit of or a

may benefit from higher anticoagulation doses. Hypotheses for this

sepsis-induced coagulopathy score of ≥4. These results mirrored the

finding include (i) critically ill patients may have too much micro-

results of the ATTACC/ACTIV-4a/REMAP-C AP outcomes and found

thrombosis, and it is too late for higher doses of anticoagulation to

that therapeutic-dose LMWH reduced thromboembolism and death

have an effect; or (ii) micro pulmonary hemorrhage may occur later

compared to lower-dose anticoagulation among high-risk hospital-

in the disease course. The results of ongoing trials will provide fur-

ized patients, but the treatment effect was not seen in the critically

ther data on the role of prophylactic anticoagulation versus full-dose

ill ICU patients.12 The RAPID trial randomized non-ICU patients with

anticoagulation in hospitalized non–critically ill patients.

elevated D-dimer to therapeutic- versus prophylactic-dose heparin

As over 50% of the burden of hospital-associated VTE in gen-

with a primary composite outcome of death, mechanical ventilation,

eral medical patients occurs after discharge,58 there has been an

or ICU admission and did not show statistical difference among the

increased interest in strategies around thromboprophylaxis after

two arms (OR, 0.69; 95% CI, 0.43-1.10; P = .12). However, there was

hospitalization for patients with COVID-19. Several factors includ-

a decreased rate of death at 28 days in the therapeutic arm (OR,

ing the hypercoagulability of the disease itself, but also burgeoning

0.22; 95% CI, 0.07-0.65; P = .006) as well as a decrease in the num-

caseloads during waves of the pandemic leading to earlier discharges

ber of VTE events in those who received therapeutic anticoagula-

when patients are still relatively sick, could in theory be associated

tion.54 Table 1 provides a summary of published RCTs regarding VTE

with increased risk of postdischarge thrombotic events. However,

prophylactic strategy in the hospitalized patients with COVID-19.

data from observational studies are mixed. A single-center retro-

It is accepted that higher doses of anticoagulation generally

spective study demonstrated that the rates of postdischarge VTE in

correlate with increased bleeding risk. Although early reports on

patients with COVID-19 were relatively low, at 2.5%.59 A study from

COVID-19 coagulopathy were focused on thrombotic risks, there

the United Kingdom compared rates of postdischarge VTE among

have been several reports on the risk of bleeding in this hospitalized

patients with COVID-19 against hospitalized medical patients from

population.36,55,56 The risk of bleeding in patients with COVID-19

the year prior, and did not find a significantly higher rate in patients

receiving higher-
than-
prophylactic anticoagulation was recently

who were admitted with COVID-19 (OR, 1.6; 95% CI, 0.77-3.1).60

evaluated using the prospective RIETE-BLEEDING registry, which

On the other hand, a recently published prospective registry study

enrolled hospitalized patients with COVID-19 who received inter-

from a US health care system found that the 90-day venous throm-

mediate or therapeutic anticoagulation for VTE prophylaxis. Over a

botic event rate was 1.55%, and that anticoagulation at discharge

short median duration (12 days), 5.7% of patients developed a major

was associated with a significant reduction in the combined out-

bleed, and 6.7% developed nonmajor bleeding. Major bleed was as-

come of venous/arterial thromboembolism and all-cause mortality

sociated D-dimer >10 times the upper limit of normal, elevated fer-

(OR, 0.54; 95% CI, 0.47-0.81).61 Several studies are currently enroll-

ritin, ICU stay, and therapeutic-level anticoagulation and correlated

ing patients, which will provide evidence to guide clinicians on this

This study, however, did not

topic.62 One such trial, the MICHELLE trial, was recently presented

compare bleeding outcomes to those on standard doses of antico-

in abstract form by Dr Eduardo Ramacciotti at the European Society

with a twofold higher risk of death.

57

agulation, and it was a noninterventional descriptive study. In the

of Cardiology Virtual Congress in August 2021. This study evaluated

previously mentioned INSPIRATION trial, critically ill patients who

rivaroxaban 10 mg daily versus placebo in patients with COVID-19
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discharged from the hospital. The composite primary outcome of

parenteral agents for hospitalized patients with COVID-19–related

symptomatic VTE, VTE-related death, bilateral VTE, symptomatic

VTE.64-67 For acutely ill patients who are admitted to the hospital,

arterial thromboembolism, myocardial infarction, nonhemorrhagic

initiation of parenteral anticoagulation with UFH or LMWH should

stroke, major adverse limb event, or cardiovascular death at 35 days

be preferred. Parenteral anticoagulation offers numerous advantages

was 3.14% in the rivaroxaban group compared with 9.43% in the

and have been extensively studied and used over the years for treat-

control group (P = .03). While we await final publication and further

ment of VTE with a good efficacy and safety profile. They are more

data, clinicians may individualize decisions around postdischarge an-

easily reversible compared to fondaparinux or DOACs.

ticoagulation based on known prothrombotic risk factors (eg, severe
immobility, personal history of VTE, known thrombophilia, cancer).

The initial choice between UFH and LMWH should be determined
on the basis of the patient’s clinical parameters like hemodynamic sta-

The outpatient setting is another arena in which the use of

bility, renal function, and the potential need for invasive procedures.

prophylactic anticoagulation has been investigated. The random-

In non–critically ill inpatients, LMWH is the preferred first-line agent

ized double-blind placebo-controlled, National Institutes of Health

for treatment of VTE because it does not require laboratory monitor-

ACTIV-4B trial was developed to determine if symptomatic outpa-

ing and minimizes exposure and personal protective equipment use.

tients with COVID-19 would benefit from prophylactic anticoagulant

For patients with contraindications to LMWH, UFH should be used

or antiplatelet agents. Patients were randomized to a 45-day course

and provides the advantage of prompt reversal of the anticoagulant

of prophylactic dose apixaban (2.5 mg orally twice daily), therapeutic-

effect with discontinuation of the infusion and protamine sulfate.

dose apixaban (5.0 mg orally twice daily), aspirin (81 mg orally twice

Monitoring UFH using aPTT can be unreliable in the setting of base-

daily), or placebo (orally twice daily). The trial was stopped early by

line abnormalities in coagulation tests,64 and patients with COVID-19

the study’s Data and Safety Monitoring Board when investigators

have been reported to have a prolonged aPTT. 22,72 Therefore, it is

found that for mildly symptomatic outpatients with COVID-19 who

important to obtain baseline aPTT before starting heparin infusion. In

were sick at home for at least a week and who remained clinically sta-

patients with a prolonged aPTT at baseline, anti-Xa assays should be

ble and had no risk factors for thrombotic events, rates of major car-

preferred for monitoring the therapeutic range of UFH.64

diopulmonary complications did not justify antithrombotic therapy.

63

Another potential issue with the use of UFH reported in some patients with COVID-19 is heparin resistance, which is defined as the

7
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need for >35 000 units of heparin in 24 hours as measured by partial
thromboplastin time.73,74 White et al73 reported heparin resistance in
8 of 10 ICU patients on UFH, and Beun et al74 reported very high doses

Patients with COVID-19 with confirmed VTE or high suspicion of

of UFH to achieve appropriate aPTT. They noted that factor VIII and

VTE should be treated with full-dose anticoagulation. Currently,

fibrinogen levels were extremely high in patients with COVID-19 and

there are no randomized trials exploring the therapeutic efficacy

was likely responsible for decreasing aPTT in in vitro assays but less

of different agents, dosing, duration, safety, or bleeding risks in

likely to affect anti-Xa levels. Therefore, monitoring of antithrombotic

these patients. Current treatment protocols for managing VTE in

activity by measuring anti-Xa levels may be more appropriate.64,65

patients with COVID-19 are primarily extrapolated from preexist-

Use of DOACs in hospitalized patients with COVID-19 requires

ing evidence-based management of VTE in patients without COVID.

caution because of the potential for significant drug-drug interac-

Therapeutic anticoagulation with unfractionated heparin (UFH),

tions with investigational antiviral therapies since both use cyto-

LMWH, direct oral anticoagulants (DOACs) or vitamin K antagonists

chrome P450 isozymes (CYP3A4) and P-glycoprotein (P-gp) drug

(eg, warfarin) remain the mainstay of treatment.64-67 Since the co-

transporter pathways.75,76 Inhibition of these pathways can result in

existence of COVID-19 and PE, two life-threatening illnesses, in the

increased levels of DOACs, while induction can result in lower levels.

same patient presents a unique challenge, the National Pulmonary

Testa et al76 reported that patients with COVID-19 treated with the

Embolism Response Team recently released a position paper that

antiviral drugs lopinavir, ritonavir, or darunavir, which are inhibitors

specifically addresses issues related to the diagnosis and manage-

of CYP3A4/P-gp pathways, resulted in significantly elevated DOAC

ment of PE in patients with COVID-19.

68

levels. The C-trough levels for DOACs were more than six times
higher during hospitalization compared to prehospitalization levels.

7.1 | Choice of anticoagulant during
hospital admission

7.2 | Choice of anticoagulant at discharge

Clinical practice guidelines for treatment of VTE in patients without

At the time of discharge, clinicians should reassess the choice of an-

COVID-19 recommend use of DOACs for most patients.69-71 However,

ticoagulant to be prescribed for outpatient treatment. The available

the risk of rapid clinical decompensation in patients with COVID-19,

options are LMWH, DOACs, and vitamin K antagonists. DOACs are

alterations in renal function, and drug interactions with various inves-

the guideline-based preferred anticoagulant for the treatment of

tigational therapies (including dexamethasone) can alter pharmaco-

VTE and result in less bleeding compared to VKAs.69-71 Selection of a

dynamics of DOACs. Therefore, current guidelines recommend using

specific DOAC agent needs to be based on individual patient-specific

|
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TA B L E 2 Clinical studies evaluating mitigation strategies of venous thromboembolism in inpatients with COVID-19 listed on the
clinicaltrials.gov website on December 16, 2021
ClinicalTrials.gov
identifier

Title of study

Question/outcome(s) of
interest

Comparator arms

Status
(12/16/2021)

Outpatient setting (prehospital)
NCT04508023

A Study of Rivaroxaban to Reduce
the Risk of Major Venous and
Arterial Thrombotic Events,
Hospitalization and Death in
Medically Ill Outpatients With
Acute, Symptomatic Coronavirus
Disease 2019 (COVID-19)
Infection (PREVENT-HD)

Evaluate the safety and
efficacy of prophylactic
dose of rivaroxaban to
reduce thrombotic events,
hospitalization, and
death in outpatients with
symptomatic SARS-CoV-2
infection

Prophylactic rivaroxaban
(10 mg daily) vs placebo

Recruiting

NCT04400799

Enoxaparin for Primary
Thromboprophylaxis in
Ambulatory Patients With
COVID-19

Age ≥50 y; primary outcome
of hospitalization and all-
cause death

Enoxaparin 40 mg daily vs no
treatment

Recruiting

Moderate-severe hospitalized patients
NCT04416048

Effect of Anticoagulation Therapy on
Clinical Outcomes in COVID-19
(COVID-PREVENT)

Rivaroxaban for the
prevention of thrombotic
events and all-c ause
mortality in patients
with moderate to severe
COVID-19

Rivaroxaban 20 mg daily ×
7 days or hospital discharge
followed by rivaroxaban
10 mg daily for 28 days
vs standard of care
thromboprophylaxis

Recruiting

NCT04505774

Accelerating COVID-19 Therapeutic
Interventions and Vaccines 4
ACUTE (ACTIV-4A)

21-day organ support–free
days. Secondary outcomes
include thrombotic events
and all-c ause mortality

Therapeutic-dose
anticoagulation vs
prophylactic-dose
anticoagulation, vs
therapeutic anticoagulation
+P2Y12 inhibitor vs
prophylactic anticoagulation
+P2Y12 inhibitor

Recruiting

NCT04373707

Effectiveness of Weight-Adjusted
Prophylactic Low Molecular
Weight Heparin Doses
Compared With Lower Fixed
Prophylactic Doses to Prevent
Venous Thromboembolism in
COVID-2019 (The Multicenter
Randomized Controlled Open-
label Trial COVI-DOSE)

Risk of DVT or PE or VTE-
related death

Standard prophylactic dose
LMWH vs weight-adjusted
prophylactic dose LMWH

Recruiting

NCT04730856

Standard vs High Prophylactic Doses
or Anticoagulation in Patients
With High Risk of Thrombosis
Admitted With COVID-19
Pneumonia (PROTHROMCOVID)

Risk of thrombotic events, use
of mechanical ventilation,
length of hospitalization,
length of ICU stay, overall
survival

Tinzaparin 4500 UI/day vs
tinzaparin 100 UI/kg/day
vs. tinzaparin 175 UI/kg/day

Recruiting

NCT04646655

Enoxaparin at Prophylactic or
Therapeutic Doses With
Monitoring of Outcomes
in Subjects Infected With
COVID-19: a Pilot Study
on 300 Cases Enrolled at
ASST-FBF-Sacco

Mortality rate, respiratory
failure, major bleeding;
secondary outcome
measures include DVT

Enoxaparin prophylactic dose
vs enoxaparin therapeutic
dose

Recruiting

(Continues)
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TA B L E 2 (Continued)
ClinicalTrials.gov
identifier

Title of study

Question/outcome(s) of
interest

Comparator arms

Status
(12/16/2021)

NCT04409834

A Multicenter, Randomized-
Controlled Trial to Evaluate
the Efficacy and Safety of
Antithrombotic Therapy for
Prevention of Arterial and Venous
Thrombotic Complications in
Critically Ill COVID-19 Patients

Prevention of thrombotic
events

Full-dose
anticoagulation+antiplatelet
vs full-dose anticoagulation
without antiplatelet vs
prophylactic anticoagulation
+antiplatelet vs
prophylactic anticoagulation
without antiplatelet

Recruiting

NCT04483960

Australasian COVID-19 Trial (ASCOT)
ADAptive Platform Trial (ASCOT
ADAPT)

All-c ause mortality or new
intensive respiratory
support or vasopressor/
ionotropic support

Standard-dose
thromoboprophylaxis
vs intermediate dose
thromboprophylaxis vs
therapeutic anticoagulation

Recruiting

NCT04345848

Preventing COVID-19-associated
Thrombosis, Coagulopathy
and Mortality With Low- and
High-dose Anticoagulation: a
Multicentric Randomized, Open-
label Clinical Trial

Thrombosis, DIC, and all-
cause mortality

Therapeutic LMWH or UFH vs
Prophylactic LWMH or UFH

Terminated (low
recruitment)

NCT04344756

Cohort Multiple Randomized
Controlled Trials Open-label
of Immune Modulatory Drugs
and Other Treatments in
COVID-19 Patients CORIMUNO-
COAG Trial

Survival without ventilation
and ventilator-free
survival. Secondary
outcomes include
thrombotic complications

Therapeutic anticoagulation
with tinzaparin or UFH vs
prophylactic anticoagulation

Not yet
recruiting

NCT04367831

Intermediate or Prophylactic-Dose
Anticoagulation for Venous or
Arterial Thromboembolism in
Severe COVID-19: A Cluster
Based Randomized Selection Trial
(IMPROVE-COVID)

Clinically relevant thrombotic
events

Prophylactic enoxaparin or
heparin vs intermediate
dose enoxaparin or heparin

Recruitment
completed

NCT04377997

A Randomized, Open-L abel Trial
of Therapeutic Anticoagulation
in COVID-19 Patients With an
Elevated D-Dimer

Death, cardiac arrest,
thrombotic event or
hemodynamic shock

Therapeutic anticoagulation vs
prophylactic anticoagulation

Not yet
recruiting

NCT04512079

FREEDOM COVID Anticoagulation
Strategy Randomized Trial

All-c ause mortality,
intubation, systemic VTE
or ischemic stroke

Prophylactic enoxaparin vs
full-dose enoxaparin vs
apixaban 5 mg every 12 h

Recruiting

NCT04366960

Comparison of Two Doses
of Enoxaparin for
Thromboprophylaxis in
Hospitalized COVID-19 Patients
(X-Covid 19)

Incidence of VTE

Enoxaparin 40 mg twice daily
vs enoxaparin 40 mg daily

Recruitment
completed

NCT04406389

Anticoagulation in Critically Ill
Patients With COVID-19 (The
IMPACT Trial)

30-day mortality

Therapeutic-dose
anticoagulation vs
intermediate-dose
prophylaxis

Recruiting

NCT04408235

High Versus Low LMWH Dosages
in Hospitalized Patients With
Severe COVID-19 Pneumonia and
Coagulopathy (COVID-19 HD)

Clinical worsening defined
by death, acute MI,
symptomatic arterial or
venous thromboembolism,
need for advanced
respiratory support.

Low-Dose LMWH group
(4000 IU daily) vs. High-
Dose LMWH (70 IU/kg
every 12 h)

Not yet
recruiting

NCT04360824

COVID-19-associated Coagulopathy:
Safety and Efficacy of
Prophylactic Anticoagulation
Therapy in Hospitalized Adults
With COVID-19

All-c ause mortality

Prophylactic-dose enoxaparin
vs intermediate-dose
enoxaparin

Recruiting
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TA B L E 2 (Continued)
ClinicalTrials.gov
identifier

Title of study

Question/outcome(s) of
interest

Comparator arms

Status
(12/16/2021)

NCT04351724

Austrian CoronaVirus Adaptive
Clinical Trial (COVID-19)
(ACOVACT) Substudy A

Sustained improvement
(>48 h) of one point on the
World Health Organization
Scale

Rivaroxaban 5 mg twice
daily vs local standard
thromboprophylaxis

Recruiting

NCT04829552

Prophylactic vs Therapeutic
Dose Anticoagulation
in COVID-19 Infection at the
Time of Admission to Critical Care
Units

All-c ause mortality

LMWH 40 mg daily or UFH
5000 IU two or three times
daily vs LMWH 1 mg/kg
twice or 1.5 mg/kg/d or
continuous infusion of UFH

Recruitment
complete

NCT04508439

Effect of the Use of Anticoagulant
Therapy During Hospitalization
and Discharge in Patients With
COVID-19 Infection

Ventilatory support time,
length of hospital stay,
mortality rate

Prophylactic vs therapeutic
enoxaparin

Recruiting

NCT04542408

Hamburg Edoxaban for
Anticoagulation in COVID-19
Study (HERO-19)

All-c ause mortality and/
or VTE and/or arterial
thromboembolism

Prophylactic vs therapeutic
enoxaparin

Recruiting

NCT04600141

Clinical Efficacy of Heparin and
Tocilizumab in Patients With
Severe COVID-19 Infection
(HEPMAB)

Clinical improvement within
30 days, defined by
hospital discharge or
clinical status

Prophylactic vs therapeutic
anticoagulation (UFH or
LMWH in each group)

Recruiting

NCT04604327

Comparison of Two Different Doses
of Bemiparin in COVID-19
(BEMICOP)

Death, ICU admission,
mechanical ventilator
support, progression to
ARDS, arterial or venous
thrombosis

Prophylactic bemiparin vs
therapeutic bemiparin

Recruiting

NCT04420299

Clinical Trial on the Efficacy and
Safety of Bemiparin in Patients
Hospitalized Because of
COVID-19

Death, ICU admission,
mechanical ventilator
support, progression to
ARDS, arterial or venous
thrombosis

Prophylactic bemiparin vs
therapeutic bemiparin

Recruiting

Postdischarge thromboprophylaxis
NCT04662684

Medically Ill Hospitalized Patients for
COVID-19 Thrombosis Extended
Prophylaxis With Rivaroxaban
Therapy: The MICHELLE Trial

VTE and VTE-related death

Rivaroxaban 10 mg daily vs no
intervention

Abstract
available

NCT04650087

COVID-19 Post-hospital Thrombosis
Prevention Trial: An Adaptive,
Multicenter, Prospective,
Randomized Platform Trial
Evaluating the Efficacy and Safety
of Antithrombotic Strategies
in Patients With COVID-19
Following Hospital Discharge

Thrombotic events and all-
cause mortality

Apixaban 2.5 mg twice daily vs
placebo

Recruiting

NCT04508439

Effect of the Use of Anticoagulant
Therapy During Hospitalization
and Discharge in Patients With
COVID-19 Infection

Thrombotic complications

Rivaroxaban 10 mg PO daily vs
only clinical follow-up

Recruiting

NCT04542408

Hamburg Edoxaban for
Anticoagulation in COVID-19
Study (HERO-19)

All-c ause mortality and/
or VTE and/or arterial
thromboembolism

Edoxaban 60 mg daily vs
placebo

Recruiting

Abbreviations: ARDS, acute respiratory distress syndrome; DIC, disseminated intravascular coagulation; DVT, deep vein thrombosis; ICU, intensive
care unit; LMWH, low-molecular-weight heparin; MI, myocardial infarction; PE, pulmonary embolism; SARS-CoV-2, severe acute respiratory
syndrome coronavirus 2; UFH, unfractionated heparin; VTE, venous thromboembolism.
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F I G U R E 2 Emerging data to answer clinical queries surrounding COVID-19 infection and risk of venous thrombosis. NCT04780295:
COVID-19 Registry on Thrombosis Complications (CORE-THROMB). NCT04535128: COVID-19 Registry to Assess Frequency, Risk Factors,
Management, and Outcomes of Arterial and Venous Thromboembolic Complications (CORONA-V TE-NET). NCT04505774: Accelerating
COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (ACTIV-4A). NCT04646655: Enoxaparin at Prophylactic or Therapeutic Doses
in COVID-19 (EMOS-COVID). NCT04409834: Prevention of Ateriovenous Thrombotic Events in Critically Ill COVID-19 Patients Trial
(COVID-PACT). NCT04344756: Trial Evaluation Efficacy and Safety of Anticoagulation in Patients with COVID-19 Infection, Nested in the
Corimmuno-19 Cohort (CORIMMUNO-COAG). NCT04377997: Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in
Hospitalized Patients with COVID-19. NCT04512079: FREEDOM COVID-19 Anticoagulation Strategy (FREEDOM COVID). NCT04406389:
Anticoagulation in Critically Ill Patients with COVID-19 (The IMPACT Trial). NCT04865913: Venous Thrombosis Virtual Surveillance in
COVID (VVIRTUOSO). NCT04662684: Medically Ill Hospitalized Patients for COVID-19 Thrombosis Extended Prophylaxis with Rivaroxaban
Therapy: The MICHELLE Trial. NCT04650087: COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis. NCT04508439:
Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection. NCT04542408:
Hamburg Edoxaban for Anticoagulation in COVID-19 Study (HERO-19). NCT04367831: Intermediate or Prophylactic-Dose Anticoagulation
for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID).
NCT04409834: Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial (COVID-PACT). NCT04829552:
Prophylactic vs Therapeutic Dose Anticoagulation in COVID-19 Infection at the Time of Admission to Critical Care Units. Please note this list
is not meant to be exhaustive, but rather illustrate the vast number of studies occurring in each of the areas of interest. ICU, intensive care
unit; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VTE, venous thromboembolism
factors including renal function, hepatic function, and insurance
coverage. Of note, dabigatran and endoxaban are approved after an

7.3 | Use of thrombolytic agents in patients with
COVID-19

initial parenteral lead-in. It is also important to screen for drug-drug
interactions as above. A useful online resource for assessing interactions is available at www.covid19-druginterac tions.org.

Wang et al77 reported three cases involving administration of tissue-
type plasminogen activator (t-PA) in patients with COVID-19 hav-

For patients with contraindications to DOACs, LMWH,

ing acute respiratory distress syndrome and all three cases showed

fondaparinux, or VKAs should be considered. LMWH or fondaparinux

limited initial evidence of decreased oxygen requirements and ven-

offers the advantage of avoiding INR checks and minimizing contact

tilatory support. Barrett et al78 reported a case series of 5 patients

with health care settings. Patients reluctant to self-administer injec-

with respiratory failure treated with systemic t-PA, some of which

tions, or having contraindications, will need a VKA. It is imperative

resulted in improved but transient respiratory status. Overall, use

for hospitals and anticoagulation clinics to set up protocols to ensure

of these fibrinolytic therapies should be reserved for current estab-

safe monitoring of INRs for outpatients.

lished indications as in patients without COVID.64,65,67
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7.4 | Duration of anticoagulation
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AC K N OW L E D G M E N T S
This work was authored by members of a steering committee

VTE associated with COVID-19 should be treated for at least

at the National Blood Clot Alliance and supported by subcon-

3 months.64-66 If there are no ongoing risk factors, it seems reasonable to

tract (02-21-8813) from the Association of University Centers

classify this type of VTE as provoked by a transient strong risk factor, and

on Disabilities (AUCD), under a cooperative agreement between

69-71

stopping therapy at 3 months, in line with prepandemic guidelines.

AUCD and the Centers for Disease Control and Prevention (CDC)
(6 NU38OT000280-02-02). The findings and conclusions of this re-

8 | U N A N S W E R E D QU E S TI O N S/FU T U R E
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view are those of the authors and do not necessarily represent the
official positions of the CDC or the AUCD.
R E L AT I O N S H I P D I S C LO S U R E

Several questions in the field of COVID-19–related VTE remain
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unanswered, and there is an urgent need for high-quality data. Key

and Osmosis Research; and consulting fees from Janssen, Pfizer,

questions that remain unanswered include:

Portola/Alexion, Bristol-Myers Squibb, Novartis, CSL Behring, and
Gilead. RZ reports consulting fees from Amagma Therapeutics and

1. What are the appropriate risk assessment models to estimate

is a stockholder for Amagma Therapeutics. RR reports grants or con-

VTE and bleeding risk in hospitalized patients with COVID-19?

tracts from Bristol-Myers Squibb and Janssen; and consulting fees

2. Should providers use higher doses of prophylactic anticoagulation

from Bristol-Myers Squibb, Janssen, Dova, and Inari. She is vice presi-

in certain patients with COVID-19?
3. What is the optimal approach to patients on full-dose anticoagulation who are admitted to the ICU during their hospitalization?

dent and serves on the Executive Committee and Board of Directors
of the Pulmonary Embolism Response Team. AK reports consulting
fees from Janssen, Bayer, Sanofi, Pfizer, and Anthos; payment for ex-

4. What is the role for extended VTE prophylaxis?

pert testimony; participation on DSMB for Jannsen, Bayer, Pfizer, and

5. What is the best approach to manage arterial thrombosis in the

Sanofi; chair of the National Blood Clot Alliance Medical and Scientific

setting of SARS-CoV-2 infection?

Advisory Board. DA. SP, RP, PE, and WR report no conflicts of interest.

Ongoing registries such as CORONA VTE NET, CORE-
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THROMBOSIS, VVIRTUOSO, CORE 19, and other multicenter co-
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hort studies have been developed to study the epidemiology, risk
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factors, prevention, management, and thromboembolic outcomes
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in patients with COVID-19. Along with these registries, there has
been an intense interest and explosion of randomized trials to an-
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CO N C LU S I O N

The COVID-19 pandemic has affected hundreds of millions of people
worldwide, and it is known that SARS-CoV-2 infection is associated
with coagulopathy and an increased risk of VTE. The pathophysiology
of thrombosis in severely ill patients with COVID-19 is likely multifactorial due to an intense immune-inflammatory response, endothelial
injury, and microvascular thrombosis. Worldwide, the medical community has worked tirelessly to improve prediction, diagnostic approach,
prevention, and treatment of VTE in these patients. Despite these
efforts, the optimal VTE prediction tools, thromboprophylaxis, and
treatment strategies are still not clear. Many well-designed prospective studies are under way to optimize our clinical approach to these
patients. Given the recent resurgence of COVID-19 cases, the medical
community will continue to press forward in effort to provide high-
quality data to help answer these important questions.
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